IL11 and periodontal disorder: It has been reported that the twice-weekly administration of recombinant human IL-11 in periodontal disease model acted by blocking proinflammatory cytokines, leading to a reduction in attachment loss and bone resorption and improvement of the inflammatory reaction [14].